Arsanis, Inc. (ASNS)

Recent filings

Arsanis, Inc. releases salary data. CEO sees compensation rise 21% - May 22, 2019

Departure of Directors or Certain - May 17, 2019

Arsanis, Inc. Just Filed Its Quarterly Report: 15. Net Loss per... - May 15, 2019

Financial Statements and - May 13, 2019

Statement of acquisition of beneficial ownership by individuals - May 10, 2019

Arsanis, Inc.'s Chief Medical Officer was just granted 37,170 options - April 26, 2019

Arsanis, Inc.'s See Remarks just declared ownership of no shares of Arsanis, Inc. - April 26, 2019

Paula Ragan, Ph.D. just provided an update on activist position in Arsanis, Inc. - April 26, 2019

Mark N. Lampert just provided an update on share ownership of Arsanis, Inc. - April 23, 2019

Bihua Chen just provided an update on share ownership of Arsanis, Inc. - April 22, 2019

OrbiMed Advisors LLC just provided an update on share ownership of Arsanis, Inc. - April 19, 2019

James E. Flynn just provided an update on share ownership of Arsanis, Inc. - April 16, 2019

Arsanis: X4 Pharmaceuticals Prices $85.8 Million Public Offering Of Common Stock And Class A Warrants - April 15, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - April 15, 2019

Filing under Securities Act Rules 163/433 of free writing prospectuses - April 12, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - April 12, 2019

Arsanis: X4 Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Class A Warrants - April 12, 2019

Arsanis: Description Of The Business Of X4 Pharmaceuticals, Inc Overview - April 11, 2019

Arsanis: Index To Consolidated Financial Statements - April 3, 2019

Arsanis, Inc. director was just granted 28,424 options - April 2, 2019

Arsanis, Inc. director was just granted 77,650 options - April 2, 2019

Arsanis, Inc. director was just granted 77,178 options - April 2, 2019

Arsanis, Inc. director was just granted 6,854 options - April 2, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - April 2, 2019

Departure of Directors or Certain - April 2, 2019

Arsanis: Genetic Mutations In Cxcr4 Create Abnormal Trafficking Of White Blood Cells (Wbcs) - April 1, 2019

Securities to be offered to employees in employee benefit plans - March 25, 2019

Paula Ragan, Ph.D. just provided an update on activist position in Arsanis, Inc. - March 22, 2019

OrbiMed Capital GP IV LLC just provided an update on activist position in Arsanis, Inc. - March 19, 2019

Arsanis, Inc.'s See Remarks was just granted 62,633 options - March 15, 2019

Melinda French Gates just provided an update on share ownership of Arsanis, Inc. - March 15, 2019

Arsanis, Inc. director was just granted 21,570 options - March 14, 2019

Arsanis, Inc. director was just granted 70,796 options - March 14, 2019

Arsanis, Inc. director was just granted 70,324 options - March 14, 2019

Arsanis, Inc.'s See Remarks was just granted 62,633 options - March 14, 2019

Arsanis, Inc.'s President and CEO just picked up 181,366 shares - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc. director just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc.'s See Remarks just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

Arsanis, Inc.'s President and CEO just declared ownership of no shares of Arsanis, Inc. - March 14, 2019

X4 Pharmaceuticals Completes Merger With Arsanis - March 13, 2019

Securities to be offered to employees in employee benefit plans - March 11, 2019

Arsanis, Inc. Just Filed Its Annual Report: 15. Net Loss pe... - March 11, 2019

Arsanis: Fee Computed On Table Below Per Exchange Act Rules - March 8, 2019

Entry into a Material Definitive - March 8, 2019

Prospectuses and communications, business combinations - March 8, 2019

Termination of a Material Definitive - March 1, 2019

Prospectuses and communications, business combinations - March 1, 2019

Arsanis: Fee Computed On Table Below Per Exchange Act Rules - March 1, 2019

Arsanis, Inc. Just Received a Notice of Effectiveness - Feb. 19, 2019

Arsanis, Inc. Just Received a Notice of Effectiveness - Feb. 14, 2019

Registration of securities, business combinations - Feb. 13, 2019

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an - Feb. 8, 2019

Registration statement under Securities Act of 1933 - Jan. 25, 2019

Departure of Directors or Certain - Jan. 16, 2019

Registration of securities, business combinations - Dec. 20, 2018

Prospectuses and communications, business combinations - Dec. 20, 2018

Entry into a Material Definitive - Dec. 20, 2018

just provided an update on activist position in Arsanis, Inc. - Dec. 6, 2018

President of Arsanis, Inc. just picked up 250,000 shares - Nov. 28, 2018

Prospectuses and communications, business combinations - Nov. 27, 2018

Arsanis, Inc. And X4 Pharmaceuticals, Inc. Conference Call - Nov. 27, 2018

Arsanis: Phase 3 Trial Of X4P-001 In Whim – Expected Initiation In 1H 2019 Meets Entry Criteria X4P-001 (N=9) Placebo (N=9) 52 Weeks Establish Auc Baseline 1 - Nov. 27, 2018

Prospectuses and communications, business combinations - Nov. 27, 2018

Arsanis Reports Financial Results For Third Quarter 2018 - Nov. 9, 2018

Arsanis, Inc. Just Filed Its Quarterly Report: 9. Net Loss pe... - Nov. 9, 2018

Arsanis, Inc. Just Filed Its Quarterly Report: 9. Net Loss pe... - Aug. 13, 2018

Major owner of Arsanis, Inc. just declared owning 2,000,000 shares of Arsanis, Inc. - July 17, 2018

Major owner of Arsanis, Inc. just declared owning 2,000,000 shares of Arsanis, Inc. - July 17, 2018

Arsanis Provides Update Following Completion Of Planned Interim Analysis - June 28, 2018

Entry into a Material Definitive - June 12, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Submission of Matters to a Vote of Security - June 7, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Arsanis, Inc. director was just granted 10,000 options - June 7, 2018

Arsanis Reports Business Highlights And Financial Results For First Quarter 2018 - May 10, 2018

Arsanis, Inc. Just Filed Its Quarterly Report: 14. Net Loss p... - May 10, 2018

Arsanis, Inc. releases salary data. CEO sees compensation rise 47% - April 23, 2018

Arsanis, Inc.'s Chief Scientific Officer was just granted 45,000 options - March 9, 2018

Arsanis Reports Financial Results And Highlights For Fourth Quarter And Full Year 2017 - March 9, 2018

Arsanis: Documents Incorporated By Reference - March 9, 2018

Securities to be offered to employees in employee benefit plans - March 9, 2018

Arsanis, Inc.'s Chief Medical Officer was just granted 50,000 options - March 9, 2018

Arsanis, Inc.'s President and CEO was just granted 160,000 options - March 9, 2018

Arsanis, Inc.'s COO and CFO was just granted 110,000 options - March 9, 2018

Arsanis, Inc.'s Chief Development Officer was just granted 50,000 options - March 9, 2018

Arsanis, Inc. director was just granted 25,000 ownership of the company. - March 8, 2018

Arsanis, Inc. director was just granted 25,000 options - March 5, 2018

Arsanis, Inc. director was just granted 25,000 options - March 5, 2018

Arsanis, Inc. director was just granted 25,000 ownership of the company. - March 5, 2018

Arsanis, Inc. director was just granted 25,000 ownership of the company. - March 5, 2018

Melinda French Gates just provided an update on share ownership of Arsanis, Inc. - Feb. 13, 2018

Statement of acquisition of beneficial ownership by individuals - Feb. 13, 2018

OrbiMed Capital GP IV LLC just provided an update on activist position in Arsanis, Inc. - Jan. 26, 2018

Statement of acquisition of beneficial ownership by individuals - Dec. 11, 2017

Notice of Exempt Offering of Securities, item 06c - Dec. 4, 2017

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. VANGUARD GROUP INC 318,295 N/A Dec. 31, 2018
2. VANGUARD GROUP INC 285,839 N/A Sept. 30, 2018
3. VANGUARD GROUP INC 285,839 N/A Sept. 30, 2018
4. BlackRock Inc. 254,180 N/A Dec. 31, 2018
5. JPMORGAN CHASE & CO 232,596 N/A Dec. 31, 2017
6. BlackRock Inc. 226,638 N/A Sept. 30, 2018
7. CITIGROUP INC 126,435 N/A Sept. 30, 2018
8. NORTHERN TRUST CORP 54,563 N/A Dec. 31, 2018
9. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
10. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
11. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
12. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
13. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
14. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
15. NORTHERN TRUST CORP 50,240 N/A June 30, 2018
16. NORTHERN TRUST CORP 32,097 N/A March 31, 2018
17. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
18. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
19. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
20. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
21. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
22. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
23. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
24. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
25. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
26. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
27. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
28. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
29. MORGAN STANLEY 13,387 N/A Sept. 30, 2018
30. MORGAN STANLEY 13,387 N/A Sept. 30, 2018

Arsanis, Inc. (ASNS)

140

cctranscripts

yesterday

Arsanis, Inc. releases salary data. CEO sees compensation rise 21% http://www.conferencecalltranscripts.org/pink/summary?id=6246492

cctranscripts

May 17, 2019

Departure of Directors or Certain http://www.conferencecalltranscripts.org/pink/summary?id=6229297

cctranscripts

May 15, 2019

Arsanis, Inc. Just Filed Its Quarterly Report: 15. Net Loss per... http://www.conferencecalltranscripts.org/pink/summary?id=6215918

cctranscripts

May 13, 2019

Financial Statements and http://www.conferencecalltranscripts.org/pink/summary?id=6196144

cctranscripts

May 10, 2019

Statement of acquisition of beneficial ownership by individuals http://www.conferencecalltranscripts.org/pink/summary?id=6185494

cctranscripts

April 26, 2019

Arsanis, Inc.'s See Remarks just declared ownership of no shares of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6109280

cctranscripts

April 26, 2019

Arsanis, Inc.'s Chief Medical Officer was just granted 37,170 options http://www.conferencecalltranscripts.org/pink/summary?id=6109281

cctranscripts

April 26, 2019

Paula Ragan, Ph.D. just provided an update on activist position in Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6107699

cctranscripts

April 23, 2019

Mark N. Lampert just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6084724

cctranscripts

April 22, 2019

Bihua Chen just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6080794

cctranscripts

April 19, 2019

OrbiMed Advisors LLC just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6079337

cctranscripts

April 16, 2019

James E. Flynn just provided an update on share ownership of Arsanis, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=6062958

cctranscripts

April 15, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities http://www.conferencecalltranscripts.org/pink/summary?id=6057611

cctranscripts

April 15, 2019

Arsanis: X4 Pharmaceuticals Prices $85.8 Million Public Offering Of Common Stock And Class A Warrants http://www.conferencecalltranscripts.org/pink/summary?id=6057631

cctranscripts

April 12, 2019

Arsanis, Inc. just filed a prospectus, suggesting it plans to soon issue some securities http://www.conferencecalltranscripts.org/pink/summary?id=6049430

cctranscripts

April 12, 2019

Filing under Securities Act Rules 163/433 of free writing prospectuses http://www.conferencecalltranscripts.org/pink/summary?id=6050496

cctranscripts

April 12, 2019

Arsanis: X4 Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Class A Warrants http://www.conferencecalltranscripts.org/pink/summary?id=6049423

cctranscripts

April 11, 2019

Arsanis: Description Of The Business Of X4 Pharmaceuticals, Inc Overview http://www.conferencecalltranscripts.org/pink/summary?id=6046223

cctranscripts

April 3, 2019

Arsanis: Index To Consolidated Financial Statements http://www.conferencecalltranscripts.org/pink/summary?id=6008980

cctranscripts

April 2, 2019

Arsanis, Inc. director was just granted 28,424 options http://www.conferencecalltranscripts.org/pink/summary?id=6006582
 


Feedback